Insights
Insights From Our Experts
Articles
Uncovering the Drivers of Satisfaction for Patient Services
As the needs of patients and healthcare providers evolve, it is essential to continuously adapt support services to meet these changing demands. Dive into our latest article to discover strategies for improving patient and provider experiences…
The Evidence Gap No One Talks About
In the excitement of global drug launches, a critical issue often overlooked is the lack of local clinical evidence in many Asia-Pacific countries. This gap forces healthcare providers to rely on Western data, which may not…
Unlocking Pharma Success: Mike Ryan’s Pre-Conference Talk at Reuters Pharma 2025
Mike Ryan, General Manager, Europe, at EVERSANA, connected in a conversation with PharmaShots before Reuters Pharma 2025 in Barcelona, which ran 9-11 April 2025. Mike’s discussion focused on the history of EVERSANA and how the company…
Unlock the Power of Indirect Treatment Comparisons (ITC) with Industry Experts
Are you gearing up for product launches and health technology assessment (HTA) submissions? Look no further! EVERSANA is proud to announce an exclusive course at the ISPOR Education Center, led by renowned experts Chris Cameron from…
CASE STUDY: Transforming Clinical Trials with EVERSANA
Modernizing Clinical Trials to Accelerate Access Clinical trials are essential for bringing life-changing therapies to market, yet traditional models often present significant barriers for both participants and trial sites. A leading pharmaceutical manufacturer partnered with EVERSANA…
Beyond Clinical Trials: Real-World Evidence Illuminates the Value of First-Line CDK4/6i in Metastatic Breast Cancer
While randomized controlled trials (RCTs) have been instrumental in establishing new standards of care, a comprehensive understanding of treatment effectiveness requires insights from real-world evidence (RWE). This is particularly true in the evolving landscape of hormone…
Case Study: Increasing Product Adoption Rate through EVERSANA’s Digital Hub Portal
Problem: Our client launched a new product in the U.S. market, but initial adoption rates were disappointingly low. Physicians, who were eager to incorporate this innovative product into their practice, hesitated to prescribe from the complexity…
Evaluating Talazoparib Plus Enzalutamide Against Standard of Care Therapies in Metastatic Castration-Resistant Prostate Cancer: A Matching-Adjusted Indirect Comparison
Posted by
Imtiaz Samjoo , Anja Haltner, MSc , Samantha Craigie , Sarah Walsh on March 27, 20253/27/25
Metastatic castration-resistant prostate cancer (mCRPC) is an incurable condition associated with poor prognosis and reduced quality of life. Historically, treatment options were limited, and despite recent advancements, the five-year survival rate for metastatic prostate cancer remains…
Optimizing Specialty Pharmacy Networks: A Best-in-Class Approach for Rare Disease Therapies
Posted by
Lindsay Reel, PharmD on March 27, 20253/27/25
For manufacturers of rare disease therapies, selecting the right specialty pharmacy model is a crucial decision that directly impacts patient access, adherence and overall brand success. An exclusive specialty pharmacy model offers distinct advantages, including streamlined…
The End of the Blockbuster: Adapting to a New Pharmaceutical Landscape With a New Commercialization Model
Traditional commercialization strategies that once fueled massive growth and profitability are no longer viable in today’s complex and competitive market. High SG&A costs without resulting revenue, patent cliffs, rising patient acquisition costs, convoluted supply chain management,…